ACTELION 
By Actelion Pharmaceuticals Ltd / Dismissal of Tracleer Qui Tam Case by the US Department of Justice . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
SOUTH SAN FRANCISCO, USA and ALLSCHWIL, SWITZERLAND - 10 January 2014 - In connection with a qui tam proceeding (commonly referred as "whistleblower case"), Actelion Ltd (SIX: ATLN) previously announced in September 2010 that its fully owned US subsidiary Actelion Pharmaceuticals US, Inc. received a subpoena from the United States Attorney's Office for the Northern District of California relating, among other things, to the marketing and sales practices of Tracleer® in the United States.
Actelion Pharmaceuticals US has now learned that the United States Attorney's Office, 27 States and the District of Columbia have declined to intervene in the qui tam action. The qui tam plaintiffs thereafter voluntarily dismissed the case. The case is therefore closed. Actelion made no payment to secure this dismissal.
Tracleer is a prescription medication for the treatment of patients with pulmonary arterial hypertension.
###
NOTES TO THE EDITOR
Actelion Ltd.
Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.
Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the entire spectrum of care, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Actelion is also offering treatments for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma.
Founded in late 1997, with now over 2,400 dedicated professionals covering all key markets around the world including the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.
Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.
For further information please contact:
Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com:
http://www.actelion.com/
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
http://hugin.info/131801/R/1753892/591685.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Globenewswire
